万邦德：WP107口服溶液获药物临床试验批准

Core Viewpoint - Wanbangde (002082) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of WP107 oral solution aimed at treating "myasthenia gravis" [1] Group 1 - The approval is intended to evaluate the pharmacokinetics and safety of WP107 oral solution in subjects with generalized myasthenia gravis [1] - In December 2023, the company received orphan drug designation from the FDA for huperzine A to treat myasthenia gravis [1] - In January 2025, WP107 oral solution is expected to receive FDA approval for new drug clinical trials for treating "generalized myasthenia gravis" [1]